Trials / Completed
CompletedNCT04438304
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Clarity Pharmaceuticals Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
Detailed description
Up to 63 participants will be recruited in this study and who are confirmed or suspected to have NETs based on biochemical evidence or that of conventional anatomical or molecular imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 64Cu-SARTATE | 64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg. |
Timeline
- Start date
- 2021-03-02
- Primary completion
- 2024-11-26
- Completion
- 2024-11-26
- First posted
- 2020-06-18
- Last updated
- 2025-02-12
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04438304. Inclusion in this directory is not an endorsement.